Rocket shares promising long-term results from rare heart disease gene therapy in small study

Rock­et Phar­ma­ceu­ti­cals re­port­ed Mon­day that ben­e­fits from its Danon dis­ease gene ther­a­py were seen up to around five years af­ter treat­ment.

The Cran­bury, NJ-based biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.